Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla

Blood (2024) 144 (10): 1061–1068.

https://doi.org/10.1182/blood.2023023659

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Srichandhana Rajamouli, Eric McLaughlin, Walter Hanel, David A. Bond, Yazeed Sawalha, Timothy J. Voorhees, Lapo Alinari, Lalit Sehgal, Kami J. Maddocks, Beth Christian, Daniel Jones, Narendranath Epperla

Blood (2022) 140 (Supplement 1): 6659–6660.

https://doi.org/10.1182/blood-2022-166988

Published: 2022

Journal Articles

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma

Kaitlin Annunzio, Natalie S. Grover, Rui Li, Daniel Jones, Walter Hanel, Beth Christian, Adam J. Olszewski, Narendranath Epperla

Blood (2022) 140 (Supplement 1): 3644–3645.

https://doi.org/10.1182/blood-2022-164892

Published: 2022

Journal Articles

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

Kristin L Koenig, Prachi Jain, Ying Huang, Kerry A. Rogers, Seema A. Bhat, Jennifer A. Woyach, Michael R. Grever, Uma Borate, Alice S. Mims, Daniel Jones, Cecelia Miller, James S. Blachly, Adam S Kittai

Blood (2022) 140 (Supplement 1): 4071–4073.

https://doi.org/10.1182/blood-2022-168274

Published: 2022

Journal Articles

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Samantha M Teierle, Ying Huang, Adam S Kittai, Seema A. Bhat, Michael R. Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia Miller

Blood (2022) 140 (Supplement 1): 7016–7017.

https://doi.org/10.1182/blood-2022-163753

Published: 2022

Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Blood (2021) 138 (Supplement 1): 226.

https://doi.org/10.1182/blood-2021-152838

Published: 2021

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134386

Published: 2020

Journal Articles

Outcomes of IDH1 - and IDH2 -Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Evan C. Chen, MD, Shuli Li, PhD, Ann-Kathrin Eisfeld, MD, Marlise R Luskin, MDMS, Alice S. Mims, MD, Daniel Jones, MD PhD, Joseph H. Antin, MD, Corey Cutler, MD MPH, FRCPC, John Koreth, MBBS, DPhil, Vincent T. Ho, MD, Mahasweta Gooptu, MD, Rizwan Romee, MD, Areej El-Jawahri, MD, Steven L. McAfee, MD, Zachariah Defilipp, MD, Robert J. Soiffer, MD, Yi-Bin Chen, MD, Amir T. Fathi

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140353

Published: 2020

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Elias Jabbour, Daniel Jones, Hagop M. Kantarjian, Susan O'Brien, Constantine Tam, Charles Koller, Jan A. Burger, Gautam Borthakur, William G. Wierda, Jorge Cortes

Blood (2009) 114 (10): 2037–2043.

https://doi.org/10.1182/blood-2009-01-197715

Published: 2009

Journal Articles

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Apostolia-Maria Tsimberidou, MD, PhD, Hagop Kantarjian, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Daniel Jones, MD, Sherry Pierce, RN, Mark Brandt, BA, Michael Keating, MB, BS, Estey Estey, MD

Blood (2007) 110 (11): 1834.

https://doi.org/10.1182/blood.V110.11.1834.1834

Published: 2007

Journal Articles

Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

Hagop M. Kantarjian, Moshe Talpaz, Susan O'Brien, Daniel Jones, Francis Giles, Guillermo Garcia-Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, Jorge Cortes

Blood (2006) 108 (6): 1835–1840.

https://doi.org/10.1182/blood-2006-02-004325

Published: 2006

Journal Articles

High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations (“cuplike” nuclei)

Weina Chen, Georgios Z. Rassidakis, Jiang Li, Mark Routbort, Daniel Jones, Hagop Kantarjian, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos

Blood (2006) 108 (5): 1783–1784.

https://doi.org/10.1182/blood-2006-03-014340

Published: 2006

NARROW

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Outcomes of IDH1 - and IDH2 -Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations (“cuplike” nuclei)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only